A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Rontalizumab (Primary) ; Rontalizumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Genentech
- 10 Jun 2017 Biomarkers information updated
- 21 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2009 New trial record.